(EDA), is a regulatory body responsible for overseeing drug registration, quality control, and pharmaceutical policy in Egypt. It plays a crucial role in ensuring the safety, efficacy, and quality of pharmaceutical products in the Egyptian market. Established in 1998, the EDA was formed as an independent regulatory authority to regulate the pharmaceutical sector in Egypt.

The main products and services offered by the EDA include drug registration, evaluation of drug safety and efficacy, quality control of pharmaceutical products, and monitoring of adverse drug reactions. It also works on setting pharmaceutical policies, guidelines, and standards to maintain the integrity of the pharmaceutical sector in Egypt. On a global scale, collaborates with international regulatory authorities and organizations to exchange knowledge and information on drug regulation.

It has established partnerships with international pharmaceutical companies, research institutions, and regulatory agencies to ensure compliance with global standards. However, it is considered a leading regulatory authority in the region, with a strong reputation for effective regulation. It competes with other regulatory bodies to attract investment in the pharmaceutical sector and ensure the availability of safe and effective drugs in Egypt.

Major events and achievements of the EDA include the establishment of a state-of-the-art drug testing laboratory and the development of the National Drug Control Strategy. These initiatives aimed to strengthen the regulatory framework and enhance the efficiency of drug registration and quality control processes. As of the latest information available, the EDA continues to work towards ensuring the safety and availability of high-quality pharmaceutical products in Egypt.

It remains committed to its mission of safeguarding public health through robust regulation and enforcement. The EDA keeps updating its policies and guidelines to adapt to emerging trends and developments in the pharmaceutical industry